Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510768 | 1.00 | ADRA2A (0.53) | ADRA2ADRD3TSHRLMNADRD2 | |
| Water SCHEMBL7373734 | 0.98 | ADRA2A (0.52) | ADRA2ADRD3TSHRLMNADRD2 | |
| Ethylene Glycol SCHEMBL29225457 | 0.96 | ADRA2A (0.50) | ADRA2ADRD3TSHRLMNADRD2 | |
| SCHEMBL7377119 | 0.90 | KDM4E (0.47) | ADRA2ADRD3TSHRLMNADRD2 | |
| SCHEMBL13395713 | 0.90 | TSHR (0.47) | ADRA2ADRD3TSHRLMNADRD2 | |
| SCHEMBL24694102 | 0.88 | DRD2 (0.53) | ADRA2ADRD3TSHRLMNADRD2 | |
| SCHEMBL28430952 | 0.88 | LMNA (0.52) | ADRA2ADRD3TSHRLMNADRD2 | |
| SCHEMBL12070949 | 0.87 | GAA (0.57) | ADRA2ADRD3TSHRLMNADRD2 | |
| SCHEMBL31376269 | 0.87 | GAA (0.57) | ADRA2ADRD3TSHRLMNADRD2 | |
| SCHEMBL28339029 | 0.87 | DRD2 (0.52) | ADRA2ADRD3TSHRLMNADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504547-A | Amisulpride preparation method of the composition | 山东安弘制药有限公司 | 2025-02-25 | — | — | CN | claimed |
| US-20240279171-A1 | METHODS FOR PREPARING CRYSTALLINE FORMS OF AMISULPRIDE | SUNOVION PHARMACEUTICALS INC (US) | 2024-08-22 | — | — | US | claimed |
| CN-117185969-A | Preparation method of 4-amino-5-ethylsulfonyl-2-methoxybenzoic acid | 江苏阿尔法药业股份有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-116003304-A | Synthesis method of amisulpride | 浙江皓华制药有限公司 | 2023-04-25 | — | — | CN | claimed |
| WO-2022256482-A1 | METHODS FOR PREPARING CRYSTALLINE FORMS OF AMISULPRIDE | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | WO | claimed |
| CN-113061108-A | Synthesis method of amisulpride process impurities | 北京万全德众医药生物技术有限公司 | 2021-07-02 | — | — | CN | claimed |
| CN-102838520-A | Amisulpride preparation method | BEIJING DVENTUREPHARM TECHNOLOGY DEV CO LTD | 2012-12-26 | — | — | CN | claimed |
| CN-119504547-A | Amisulpride preparation method of the composition | 山东安弘制药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119504547-A | Amisulpride preparation method of the composition | 山东安弘制药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-118993969-B | Industrial production method for amisulpride | 广州市桐晖药业有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12161623-B2 | Nonracemic mixtures and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12161758-B2 | Modified release formulations and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118993969-A | Industrial production method for amisulpride | 广州市桐晖药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-4816471-A | NERVOUS SYSTEM DISORDERS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILLE-DE FRANCE (FR) | 1989-03-28 | — | — | US | disclosed |
| US-4673686-A | CNS MODIFIERS, ANTI-APOMORPHINE ANTIENETIC ACITIVTY/ | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLE DE L'ILE DE FRANCE (FR) | 1987-06-16 | — | — | US | disclosed |
| EP-0055524-B1 | BICYCLO (3,2,1) OCTYLBENZAMIDES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1984-10-17 | — | — | EP | disclosed |
| US-4410535-A | ANTIEMETICS | BEECHAM GROUP LIMITED (GB) | 1983-10-18 | — | — | US | disclosed |
| US-4401822-A | ANISEROTONINE AGENTS; APOMORPHINE ANTAGONIST | SOCIETE DE'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE FRANCE (FR) | 1983-08-30 | — | — | US | disclosed |
| EP-0055524-A2 | Bicyclo (3,2,1) octylbenzamides, a process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1982-07-07 | — | — | EP | disclosed |
| US-4294828-A | ANTIEMETIC AND ANTISEROTONIN | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE DE-FRANCE (FR) | 1981-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161623-B2 | Nonracemic mixtures and uses thereof | TPMT, AASDHPPT, SIGMAR1 | ADRA2A 111/4885DRD3 1446/4885TSHR 2384/4885 |
| US-12161758-B2 | Modified release formulations and uses thereof | SRI, ABCG2, SUCNR1 | ADRA2A 44/4885DRD3 1089/4885TSHR 1193/4885 |
| US-20240279171-A1 | METHODS FOR PREPARING CRYSTALLINE FORMS OF AMISULPRIDE | U2SURP, HMGCR, ABCG2 | ADRA2A 246/4885DRD3 875/4885TSHR 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.